AXSM vs MMED: fair value comparison
Axsome Therapeutics, Inc. and MiniMed Group, Inc. · Updated 2026-10-19
AXSM's estimate rests on a sector-average multiple, which TickrTrends does not publish as a verdict. MMED's estimate rests on a sector-average multiple, which TickrTrends does not publish as a verdict. Within Healthcare, AXSM currently ranks higher by quality score.
| AXSM | MMED | |
|---|---|---|
| Verdict | Awaiting full valuation | Awaiting full valuation |
| Last price | $157.14 | $17.49 |
| 12-month range | $129.55–$255.17 | $12.00–$22.42 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #194 of 301 Healthcare | #196 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | High | Low |
| Margin trend | Expanding | — |
| Revenue growth | High | — |
| RSI zone | Oversold | Oversold |
| 50/200-day trend | Downtrend | — |
| 52-week position | The bottom quarter | The upper-middle quarter |
Full single-stock breakdowns: AXSM fair value analysis · MMED fair value analysis